Patisiran, an investigational intravenously administered RNAi therapeutic targeting transthyretin in development for the treatment of hereditary ATTR amyloidosis, is designed to silence specific messenger RNA, potentially blocking the production of TTR protein. This may help to enable the clearance of TTR amyloid deposits in peripheral tissues and potentially restore function to these tissues.
The safety and efficacy of patisiran have not been evaluated by the US Food and Drug Administration or any other health authority.
Alnylam has licenses to Arbutus Biopharma LNP intellectual property for use in RNA interference (RNAi) therapeutic products using LNP technology. By harnessing the natural biological process of RNAi occurring in our cells, a major new class of medicines, known as RNAi therapeutics, is on the horizon.
Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, potently silence messenger RNA, the genetic precursors that encode for disease-causing proteins, thus preventing them from being made.
Alnylam Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes novel therapeutics based on RNA interference. Its pipeline of investigational RNAi therapeutics is focused on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer